Related Experiment Video
Updated: Feb 20, 2026

Dual-Task Stroop Paradigm for Detecting Cognitive Deficits in High-Functioning Stroke Patients
Published on: December 16, 2022
Measuring informed consent capacity in an Alzheimer's disease clinical trial
Peter D Guarino1,2, Julia E Vertrees3, Sanjay Asthana4,5
1Cooperative Studies Program Coordinating Center, VA Connecticut Healthcare System, West Haven, CT, USA.
Introduction:
Accurately and efficiently determining a participant's capacity to consent to research is critically important to protect the rights of patients with Alzheimer's disease (AD).
Methods:
Understanding of the informed consent document was assessed in 613 community-dwelling patients with mild-to-moderate AD enrolled in a randomized, placebo-controlled trial. Associations were examined between clinically determined capacity to consent and (1) patient demographics and clinical characteristics and (2) the Informed Consent Questionnaire (ICQ), an objective measurement of a participant's factual understanding and perceived understanding.
Results:
A total of 453 (74%) participants were determined to have capacity to consent by clinical judgment. ICQ perceived understanding, race, measures of cognitive function, and caregiver time were all significantly associated with the determination of capacity in multivariate analyses.
Discussion:
We found a significant association between capacity and disease severity level, caregiver time, race, and ICQ perceived understanding.
More Related Videos
12:18A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
Published on: January 11, 2020
06:23The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease
Published on: October 13, 2016
Related Concept Videos
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
Alzheimer's Disease: Treatment
Dementia
The progression of dementia is generally gradual....
Bioavailability Study Design: Healthy Subjects Versus Patients